Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
MiMedx GroupMDXG +1.55%53 Forward PE Ratio is 201.27 as of Jul. 15, 2026. GuruFocus rates MDXG with a GF Score™ of 53/100 and a GF Value™ of $6.80 (Significantly Undervalued). The stock has 2 warning signs investors should review. Among 354 Biotechnology companies, MiMedx Group ranks worse than 92.37% on this metric.
MiMedx Group's Forward PE Ratio for today is 201.27.
MiMedx Group (NAS:MDXG) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
MiMedx Group Forward PE Ratio Related Terms
MiMedx Group Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for MiMedx Group's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MiMedx Group Forward PE Ratio Chart
MiMedx Group Annual Data
Trend
2015-12
2016-12
2017-12
2023-12
2024-12
2025-12
Forward PE Ratio
23.04
30.58
45.25
23.70
30.39
28.16
MiMedx Group Quarterly Data
2015-12
2016-03
2016-06
2016-09
2016-12
2017-03
2017-06
2017-09
2017-12
2018-03
2023-03
2023-06
2023-09
2023-12
2024-03
2024-06
2024-12
2025-03
2025-06
2025-09
2025-12
2026-03
Forward PE Ratio
23.04
18.90
25.25
26.81
30.58
32.26
47.62
42.74
45.25
15.15
344.83
222.22
30.40
23.70
23.98
18.98
30.39
27.12
23.95
20.23
28.16
34.64
MDXG vs MNPR, FTH, BBOT: Forward PE Ratio Comparison
For the Biotechnology subindustry, MiMedx Group's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MiMedx Group Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, MiMedx Group's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where MiMedx Group's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
MiMedx Group (MDXG) has a Forward PE Ratio of 201.27 as of Jul. 15, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MiMedx Group and its competitors. According to the industry distribution chart, MiMedx Group ranks #327 out of 354 companies in the Biotechnology industry, placing it in the top 92.4%.
Is MiMedx Group's Forward PE Ratio too high?
MiMedx Group's current Forward PE Ratio is 201.27. The Biotechnology industry median Forward PE Ratio is 22.28. MiMedx Group's value of 201.27 is 803.4% above this industry median. Based on the distribution chart, MiMedx Group ranks #327 out of 354 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MiMedx Group has a GF Score™ of 53/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MiMedx Group's Forward PE Ratio compare to MNPR and FTH?
According to the Biotechnology industry distribution chart, MiMedx Group ranks #327 out of 354 companies for Forward PE Ratio. This places MiMedx Group in the lower half of its industry. The industry median Forward PE Ratio is 22.28. MiMedx Group's value of 201.27 is 803.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 22.28, based on 354 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MiMedx Group's current Forward PE Ratio of 201.27 is 803.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on MiMedx Group and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 22.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MiMedx Group's current Forward PE Ratio is 201.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MiMedx Group stock overvalued right now?
Based on GuruFocus' analysis, MiMedx Group (MDXG) is currently considered Significantly Undervalued. The stock's GF Value™ is $6.80, compared to a current price of $4.27 — trading 37.2% below its estimated fair value. The current Forward PE Ratio is 201.27 and 803.4% above the Biotechnology industry median of 22.28. MiMedx Group's overall GF Score™ is 53/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For MiMedx Group (MDXG), the current Forward PE Ratio is 201.27 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MiMedx Group (MDXG) Overvalued in 2026?
Based on GuruFocus' analysis, MiMedx Group stock appears to be undervalued.
The current stock price of $4.27 is trading 37.2% below its estimated GF Value™ of $6.80.
GuruFocus considers MiMedx Group to be Significantly Undervalued.
Key valuation signals for MDXG:
Forward PE Ratio: 201.27
GF Value™: $6.80 vs. price of $4.27 (37.2% below fair value)
Industry Position: 803.4% above the Biotechnology median (#327 of 354)
No single metric tells the full story. See the MDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MiMedx Group Inc develops and markets regenerative biomaterial products and bioimplants made from the human amniotic membrane, birth tissues, and human skin & bone. Its products are targeted towards the wound-care, burn, surgical, sports medicine, and orthopedics markets. MiMedx's key products are allografts processed from amniotic tissue, which include EpiFix for external use and AmnioFix for internal use. AmnioCord, AmnioFill, EpiBurn, and EpiCord are some of its other products. Also, the company sells allografts for ophthalmic surgery and dental applications through licenses to third parties.
53GF Score
Get the complete analysis for MDXG
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXG has been successfully added to your 
